Individuals with peanut allergies are at constant risk of severe reactions, and this week, we talk about new treatments with Jessica Grossman of IgGenix.
Check out a new report exploring R&D trends and breakthrough innovations leveraging antibodies to create potentially game-changing therapies, published by our parent company Inpart.
TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]